Chemical Structure (Image 01)
Rezurock Tablet
Product Images NDC 79802-200
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Rezurock (NDC 79802-200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Kadmon Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Principal Display Panel (Bottle Label)
This text describes the medication REZUROCK, which is available in tablet form containing 200 mg of belumosudil (equivalent to 242.50mg of belumosudil mesylate). The recommended dosage of REZUROCK is not listed, and users should refer to the prescribing information. The tablets should be swallowed whole and should not be chewed, cut, or crushed. The medication should be stored between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). The container should remain in the original packaging with the desiccant to protect it from moisture, and it should be kept away from children. The medication is distributed by Kadmon Pharmaceuticals, LLC, and manufactured by UPM Pharmaceuticals in Bristol, TN, and the active ingredient is made in India. The LOT and EXP are not available in the given text.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
